Shots:

• AstraZeneca and AVEO collaborates to evaluate safety and efficacy of AstraZeneca’s Imfinzi (durvalumab) + AVEO’s Fotivda (tivozanib) in P-I/II for 1L HCC or liver cancer
• AVEO plans to initiate the onset of P-I trial for the combination therapy in 2019- with equal cost sharing
• Imfinzi (durvalumab) is mAb binds with PD-L1- further blocking its interaction with PD-1 and CD80 and evaluated as monothx or in combination for multiple cancers.  Fotivda (tivozanib) PO is qd VEGF receptor tyrosine kinase inhibitor approved for advance RCC in EU

Ref: AVEO Oncology | Image: AstraZeneca